There is a race underway to develop treatments for the fatty liver disease known as NASH. And for good reason — with a massive patient population and no treatments approved yet, there is money to be made.

But the companies in this race are not all built alike. The EASL liver disease research meeting, which was just held in Vienna, Austria, however, offers an opportunity to step back and sentiment-check the stature and status of the five most prominent NASH contenders.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why are you so skeptical about Genfits GNFT Elafibranor? Ok there was a retrospective analysis for the scope of the ph3 study but nevertheless Elafibranor is very advanced and there is a chance in the interim analysis to file for conditional approval. Compared with all other NASH stocks GNFT looks really cheap with a market capitalization under to 1 billion.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy